Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for...

Area of Science:

• Oncology
• Gene Therapy
• Nanotechnology

Background:

• The Herpes simplex virus-thymidine kinase (HSV-TK)/ganciclovir (GCV) system is a promising suicide gene therapy for prostate cancer.
• Limitations include the need for effective gene vectors and specific tumor targeting.

Purpose of the Study:

• To establish and evaluate a novel nonviral gene delivery system for prostate cancer therapy.
• To assess the anti-tumor efficacy of a system co-delivering HSV-TK and connexin43 (Cx43) genes using a prostate-specific membrane antigen (PSMA) promoter.

Main Methods:

• Development of a nonviral gene vector, G5-PAMAM-D, for delivering PSMAe/p-TK-Cx43.
• Evaluation of gene expression specificity in prostate cancer cell lines (LNCaP, PC-3).
• Assessment of transfection efficiency, in vitro cell proliferation, and apoptosis induction with gemcitabine.
• In vivo evaluation of tumor growth inhibition in a LNCaP xenograft model.

Main Results:

• G5-PAMAM-D demonstrated targeted expression of HSV-TK and Cx43 in LNCaP cells.
• Transfection efficiency was comparable to commercial lipofectamine 2000.
• The combined therapy significantly inhibited LNCaP cell proliferation and induced apoptosis in vitro.
• Systemic delivery of the gene therapy significantly suppressed tumor growth in vivo.

Conclusions:

• The novel G5-PAMAM-D/PSMAe/p-TK-Cx43 system shows potent anti-tumor effects.
• This double-targeted and double-enhanced approach holds potential for prostate cancer gene therapy.
• Combination of Cx43, gemcitabine, and HSV-TK/GCV gene therapy offers a novel therapeutic strategy.